IC
MDGL icon

Innealta Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Innealta Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$560 – 1053
2024
Q2 		$560 Buy
+2
New +$476 ﹤0.01% 1453

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Innealta Capital's MDGL Position: Q3 2024 in Review

Innealta Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 2 shares — an estimated $560 sold.

Innealta Capital first reported a position in MDGL in Q2 2024 and held it in 1 quarter. The position peaked at $560 in Q2 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • Innealta Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 2 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $560.
  • Innealta Capital first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Madrigal Pharmaceuticals position peaked at $560 in Q2 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.